Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2835219 versus erlotinib in previously treated KRAS-mutant stage IV non-small cell lung cancer
2013-004662-33Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing LY2835219 plus best supportive care with erlotinib plus best supportive care (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jul 2014; status: completed.
02
Drugs
abemacicliberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-004662-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004662-33.